Combined therapy with cisplatin and interferon alpha-2b (INTRON-A) in patients with penile carcinoma. Analysis of 2'5' oligo (A) synthetase and circulating interferon.
Mouratidou
D
D
Kortsaris
A H
AH
Andreadis
C
C
Galaktidou
G
G
Vakalikos
I
I
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004790:Enzyme Induction; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000097:blood* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010412:Penile Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011994:Recombinant Proteins; D012008:Recurrence
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003404:Creatinine; D015088:2',5'-Oligoadenylate Synthetase; D002945:Cisplatin